NCT00265876 - AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 26, 2006

Primary Completion Date

January 8, 2009

Study Completion Date

January 6, 2012

Conditions

Pancreatic Cancer

Interventions

DRUG

AZD0530

Taken daily every 4 weeks

DRUG

gemcitabine hydrochloride

1000mg/m2 IV weekly

Trial Locations (4)

BCCA - Vancouver Cancer Centre, Vancouver

Ottawa Health Research Institute - General Division, Ottawa

Algoma District Cancer Program, Sault Ste. Marie

Univ. Health Network-Princess Margaret Hospital, Toronto